REGENERON PHARMACEUTICALS, INC

Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers

Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers

Patent issues relating to biopharmaceutical manufacturers; intellectual property rights; issues relating to WTO TRIPS waivers